These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21513366)

  • 1. Novel approaches to assessing cardiac safety--proceedings of a workshop: regulators, industry and academia discuss the future of in silico cardiac modelling to predict the proarrhythmic safety of drugs.
    Fletcher K; Shah RR; Thomas A; Tobin F; Rodriguez B; Mirams GR; Saiz J; Noble D
    Drug Saf; 2011 May; 34(5):439-43. PubMed ID: 21513366
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
    Zhou SB; Wang J; Liu H
    Yao Xue Xue Bao; 2016 Oct; 51(10):1530-9. PubMed ID: 29932317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D; Brown AM
    J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data.
    De Bruin ML; van Puijenbroek EP; Bracke M; Hoes AW; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):99-105. PubMed ID: 16329159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hERG potassium channels and cardiac arrhythmia.
    Sanguinetti MC; Tristani-Firouzi M
    Nature; 2006 Mar; 440(7083):463-9. PubMed ID: 16554806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
    Stansfeld PJ; Sutcliffe MJ; Mitcheson JS
    Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):81-94. PubMed ID: 16863470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Colatsky T
    J Pharmacol Toxicol Methods; 2016; 81():233-9. PubMed ID: 27178106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels.
    Lin C; Cvetanovic I; Ke X; Ranade V; Somberg J
    Am J Ther; 2005; 12(4):328-36. PubMed ID: 16041196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system].
    Chachin M; Kurachi Y
    Nihon Yakurigaku Zasshi; 2002 Jun; 119(6):345-51. PubMed ID: 12089906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hERG potassium channel as a therapeutic target.
    Witchel HJ
    Expert Opin Ther Targets; 2007 Mar; 11(3):321-36. PubMed ID: 17298291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
    DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
    J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmural and rate-dependent profiling of drug-induced arrhythmogenic risks through in silico simulations of multichannel pharmacology.
    Zhao P; Li P
    Sci Rep; 2019 Dec; 9(1):18504. PubMed ID: 31811197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dealing with hERG liabilities early: diverse approaches to an important goal in drug development.
    Guth BD; Rast G
    Br J Pharmacol; 2010 Jan; 159(1):22-4. PubMed ID: 20141517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
    Pearlstein R; Vaz R; Rampe D
    J Med Chem; 2003 May; 46(11):2017-22. PubMed ID: 12747773
    [No Abstract]   [Full Text] [Related]  

  • 19. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels].
    Nakaya H
    Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):384-92. PubMed ID: 12835532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.